Prolong Pharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: South Planfield NJ United States (2005)

Organization Overview

First Clinical Trial
2013
NCT01848925
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Prolong Pharamceuticals | Prolong Pharma | Prolong Pharmaceuticals

Active Ingredients

Drugs in Phase 3 Trials (2)

pegylated carboxyhemoglobin (11 trials)

sodium chloride (4 trials)

Drugs in Phase 2 Trials (1)

Filgrastim (neupogen) (2 trials)

Drugs in Phase 1 Trials (2)

hydroxyurea (hydrea) (1 trial)

pegylated erythropoeitin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 1)

Anemia, Sickle Cell (Phase 2)

beta-Thalassemia (Phase 1)

Brain Ischemia (Phase 2)

Cerebral Infarction (Phase 2)

Delayed Graft Function (Phase 3)

Hemorrhage (Phase 2)

Ischemia (Phase 2)

Kidney Failure, Chronic (Phase 1)

Leg Ulcer (Phase 2)

Neutropenia (Phase 2)

Renal Insufficiency (Phase 1)

Renal Insufficiency, Chronic (Phase 1)

Stroke (Phase 1)

Subarachnoid Hemorrhage (Phase 2)

Thalassemia (Phase 1)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 5